NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
PrECOG, LLC.
Fundación GECP
Bristol-Myers Squibb
Instituto Nacional de Cancerologia de Mexico
IRCCS San Raffaele
Ziauddin University